Skip to main content

Home/ Cancer/ Group items tagged October

Rss Feed Group items tagged

Matti Narkia

Bioavailability and Kinetics of Sulforaphane in Humans after Consumption of Cooked vers... - 0 views

  •  
    Bioavailability and Kinetics of Sulforaphane in Humans after Consumption of Cooked versus Raw Broccoli Martijn Vermeulen*, Ineke W. A. A. Klpping-Ketelaars†, Robin van den Berg‡ and Wouter H. J. Vaes J. Agric. Food Chem., 2008, 56 (22), pp 10505-10509 Publication Date (Web): October 24, 2008 (Article) DOI: 10.1021/jf801989e
Matti Narkia

Vitamin C Antagonizes the Cytotoxic Effects of Antineoplastic Drugs - 0 views

  •  
    Vitamin C antagonizes the cytotoxic effects of antineoplastic drugs.\nHeaney ML, Gardner JR, Karasavvas N, Golde DW, Scheinberg DA, Smith EA, O'Connor OA.\nCancer Res. 2008 Oct 1;68(19):8031-8.\nPMID: 18829561
Matti Narkia

Cannabinoids: potential anticancer agents : Abstract : Nature Reviews Cancer - 0 views

  •  
    Cannabinoids: potential anticancer agents. Guzmán M. Nat Rev Cancer. 2003 Oct;3(10):745-55. Review. PMID: 14570037 doi:10.1038/nrc1188
Matti Narkia

Structure-function relationships of anthocyanins from various anthocyanin-rich extracts... - 0 views

  •  
    Structure-function relationships of anthocyanins from various anthocyanin-rich extracts on the inhibition of colon cancer cell growth. Jing P, Bomser JA, Schwartz SJ, He J, Magnuson BA, Giusti MM. J Agric Food Chem. 2008 Oct 22;56(20):9391-8. Epub 2008 Sep 19. PMID: 18800807 DOI: 10.1021/jf8005917
Matti Narkia

Ginkgo biloba extract EGb(R)761 exerts anti-angiogenic effects via activation of tyrosi... - 0 views

  •  
    Ginkgo biloba extract EGb(R)761 exerts anti-angiogenic effects via activation of tyrosine phosphatases. Koltermann A, Liebl J, Fürst R, Ammer H, Vollmar AM, Zahler S. J Cell Mol Med. 2008 Oct 23. [Epub ahead of print] PMID: 19175691
Matti Narkia

Dichloroacetate (DCA) as a potential metabolic-targeting therapy for cancer - British J... - 0 views

  •  
    Dichloroacetate (DCA) as a potential metabolic-targeting therapy for cancer.\nMichelakis ED, Webster L, Mackey JR.\nBr J Cancer. 2008 Oct 7;99(7):989-94. Epub 2008 Sep 2. Review.\nPMID: 18766181 \ndoi:10.1038/sj.bjc.6604554 \n
Matti Narkia

Nutrition and cancer: A review of the evidence for an anti-cancer diet - Nutrition Jour... - 0 views

  •  
    Donaldson MS. Nutrition and cancer: a review of the evidence for an anti-cancer diet.\nNutr J. 2004 Oct 20;3:19. PMID: 15496224
Matti Narkia

Dichloroacetate (DCA) as a potential metabolic-targeting therapy for cancer - British J... - 1 views

  •  
    Dichloroacetate (DCA) as a potential metabolic-targeting therapy for cancer. Michelakis ED, Webster L, Mackey JR. Br J Cancer. 2008 Oct 7;99(7):989-94. Epub 2008 Sep 2. Review. PMID: 18766181 doi:10.1038/sj.bjc.6604554 The unique metabolism of most solid tumours (aerobic glycolysis, i.e., Warburg effect) is not only the basis of diagnosing cancer with metabolic imaging but might also be associated with the resistance to apoptosis that characterises cancer. The glycolytic phenotype in cancer appears to be the common denominator of diverse molecular abnormalities in cancer and may be associated with a (potentially reversible) suppression of mitochondrial function. The generic drug dichloroacetate is an orally available small molecule that, by inhibiting the pyruvate dehydrogenase kinase, increases the flux of pyruvate into the mitochondria, promoting glucose oxidation over glycolysis. This reverses the suppressed mitochondrial apoptosis in cancer and results in suppression of tumour growth in vitro and in vivo. Here, we review the scientific and clinical rationale supporting the rapid translation of this promising metabolic modulator in early-phase cancer clinical trials More than 40 nonrandomised trials of DCA in small cohorts of patients have been reported, but the first two randomised control trials of chronic oral therapy with DCA in congenital mitochondrial diseases were reported in 2006. In the first, a blinded placebo-controlled study was performed with oral DCA administered at 25 mg kg-1 day-1 in 30 patients with MELAS syndrome (mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes) (Kaufmann et al, 2006). Most patients enrolled in the DCA arm developed symptomatic peripheral neuropathy, compared with 4 out of 15 in the placebo arm, leading to the termination of the study. Seventeen out of 19 patients had at least partial resolution of peripheral neurological symptoms by 9 months after discontinuation of DCA. This neurotoxicity res
Matti Narkia

Maté: a risk factor for oral and oropharyngeal cancer - Oral Oncol. 2002 Oct;... - 0 views

  •  
    Maté: a risk factor for oral and oropharyngeal cancer. Goldenberg D. Oral Oncol. 2002 Oct;38(7):646-9. Review. PMID: 12167417
Matti Narkia

Scripps research team solves structure of 'beneficial' virus | Eureka! Science News - 0 views

  •  
    D structure of the virus, known as Seneca Valley Virus-001, reveals that it is unlike any other known member of the Picornaviridae viral family, and confirms its recent designation as a separate genus "Senecavirus." The new study reveals that the virus's outer protein shell looks like a craggy golf ball¬-one with uneven divets and raised spikes-and the RNA strand beneath it is arranged in a round mesh rather like a whiffleball. "It is not at all like other known picornaviruses that we are familiar with, including poliovirus and rhinoviruses, which cause the common cold," says the study's senior author, Associate Professor Vijay S. Reddy, Ph.D., of The Scripps Research Institute. "This crystal structure will now help us understand how Senecavirus works, and how we can take advantage of it." The Senecavirus is a "new" virus, discovered several years ago by Neotropix Inc., a biotech company in Malvern, Pennsylvania. It was at first thought to be a laboratory contaminant, but researchers found it was a pathogen, now believed to originate from cows or pigs. Further investigation found that the virus was harmless to normal human cells, but could infect certain solid tumors, such as small cell lung cancer, the most common form of lung cancer.
Matti Narkia

Multi-targeted therapy of cancer by omega-3 fatty acids - Cancer Lett. 2008 Oct 8 - 0 views

  •  
    Multi-targeted therapy of cancer by omega-3 fatty acids. Berquin IM, Edwards IJ, Chen YQ. Cancer Lett. 2008 Oct 8;269(2):363-77. Epub 2008 May 13. Review. PMID: 18479809 doi:10.1016/j.canlet.2008.03.044
Matti Narkia

Modulatory effects of EPA and DHA on proliferation and apoptosis of pancreatic cancer c... - 0 views

  •  
    It was concluded that omega-3 fatty acid could inhibit the proliferation of pancreatic cancer cell line SW1990 cells and promote their apoptosis. The down-regulation of the cyclin E expression by omega-3 fatty acid might be one of the mechanisms for its anti-tumor effect on pancreatic cancer. Modulatory effects of EPA and DHA on proliferation and apoptosis of pancreatic cancer cells. Zhang W, Long Y, Zhang J, Wang C. J Huazhong Univ Sci Technolog Med Sci. 2007 Oct;27(5):547-50. PMID: 18060632
Matti Narkia

Vitamin D and cancer Ali MM, Vaidya V - J Can Res Ther 2007 Oct-Dec - 0 views

  •  
    Vitamin D and cancer. Ali MM, Vaidya V. J Cancer Res Ther. 2007 Oct-Dec;3(4):225-30. Review. PMID: 18270398 DOI: 10.4103/0973-1482.38998
Matti Narkia

Arginine and cancer. - J Nutr. 2004 Oct - 0 views

  •  
    Arginine and cancer. Lind DS. J Nutr. 2004 Oct;134(10 Suppl):2837S-2841S; discussion 2853S. Review. PMID: 15465796
Matti Narkia

Calcium, Dairy Foods, Vitamin D, and Colorectal Cancer Risk: The Fukuoka Colorectal Can... - 0 views

  •  
    Calcium, dairy foods, vitamin D, and colorectal cancer risk: the Fukuoka Colorectal Cancer Study. Mizoue T, Kimura Y, Toyomura K, Nagano J, Kono S, Mibu R, Tanaka M, Kakeji Y, Maehara Y, Okamura T, Ikejiri K, Futami K, Yasunami Y, Maekawa T, Takenaka K, Ichimiya H, Imaizumi N. Cancer Epidemiol Biomarkers Prev. 2008 Oct;17(10):2800-7. PMID: 18843026
Matti Narkia

Vitamin D From Dietary Intake and Sunlight Exposure and the Risk of Hormone-Receptor-De... - 0 views

  •  
    Vitamin D from dietary intake and sunlight exposure and the risk of hormone-receptor-defined breast cancer. Blackmore KM, Lesosky M, Barnett H, Raboud JM, Vieth R, Knight JA. Am J Epidemiol. 2008 Oct 15;168(8):915-24. Epub 2008 Aug 27. PMID: 18756015 doi:10.1093/aje/kwn198 This study suggests that vitamin D is associated with a reduced risk of breast cancer regardless of ER/PR status of the tumor. Future studies with a larger number of receptor-negative and mixed tumors are required.
Matti Narkia

Vitamin D Is Associated with Improved Survival in Early-Stage Non-Small Cell Lung Cance... - 0 views

  •  
    Vitamin D is associated with improved survival in early-stage non-small cell lung cancer patients. Zhou W, Suk R, Liu G, Park S, Neuberg DS, Wain JC, Lynch TJ, Giovannucci E, Christiani DC. Cancer Epidemiol Biomarkers Prev. 2005 Oct;14(10):2303-9. PMID: 16214909 In conclusion, the joint effects of surgery season and recent vitamin D intake seem to be associated with the survival of early-stage non-small cell lung cancer patients.
Matti Narkia

Experimental Drug May Work In Many Cancers - 2 views

  •  
    "SCIENTISTS have shown that a new class of cancer drugs called PARP inhibitors, currently being tested in clinical trials to treat breast and ovarian cancer could have dramatic results when used to treat other solid tumours, according to work presented at the NCRI Cancer Conference today. "
Matti Narkia

Factors Associated With Clinical Benefit From Epidermal Growth Factor Receptor Inhibito... - 0 views

  •  
    Factors associated with clinical benefit from epidermal growth factor receptor inhibitors in recurrent and metastatic squamous cell carcinoma of the head and neck. Cohen EE, Halpern AB, Kasza K, Kocherginsky M, Williams R, Vokes EE. Oral Oncol. 2009 Oct;45(10):e155-60. Epub 2009 Jul 7. PMID: 19586795
Matti Narkia

Women With Breast Cancer Have Low Vitamin D Levels - 0 views

  •  
    "ScienceDaily (Oct. 8, 2009) - Women with breast cancer should be given high doses of vitamin D because a majority of them are likely to have low levels of vitamin D, which could contribute to decreased bone mass and greater risk of fractures, according to scientists at the University of Rochester Medical Center." Scientists funded by the NCI analyzed vitamin D levels in each woman, and the average level was 27 nanograms per milliliter; more than two-thirds of the women had vitamin deficiency. Weekly supplementation with high doses of vitamin D -- 50,000 international units or more -- improved the levels, according to Peppone's study. The U.S. Institute of Medicine suggests that blood levels nearing 32 nanograms per milliliter are adequate.
1 - 20 of 28 Next ›
Showing 20 items per page